http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 06:25:34 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/BioXcel+Therapeutics+files+for+Chapter+11%2C+agrees+to+sell+assets+to+Teva/26992728.html <p>BioXcel Therapeutics, Inc. (Nasdaq: BTAI) has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., and filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware, Case No. 26-11360.</p><p>The agreement covers substantially all of BioXcel's assets, including its approved drug IGALMI (dexmedetomidine) sublingual film and a pending supplemental New Drug Application for BXCL501, which targets at-home treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The FDA has assigned a PDUFA target action date of November 14, 2026, for http://www.streetinsider.com/Corporate+News/BioXcel+Therapeutics+files+for+Chapter+11%2C+agrees+to+sell+assets+to+Teva/26992728.html Fri, 28 Aug 2026 06:25:34 -0400 BTAI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioXcel+Therapeutics%2C+++++For%3A+Aug+27/26992595.html si-local-file:///var/storage/secattach/20260828/26992595.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioXcel+Therapeutics%2C+++++For%3A+Aug+27/26992595.html Fri, 28 Aug 2026 06:07:00 -0400 BTAI O.37678149 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioXcel+Therapeutics%2C+++++For%3A+Aug+27/26992595.html si-local-file:///var/storage/secattach/20260828/26992595.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioXcel+Therapeutics%2C+++++For%3A+Aug+27/26992595.html Fri, 28 Aug 2026 06:07:00 -0400 BTAI O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Press+Releases/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149 http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html <p align="center"><em>BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders</em></p> <p align="center"><em>Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process</em></p> <p align="center"><em>BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations</em></p> <p>NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva http://www.streetinsider.com/Globe+Newswire/BioXcel+Therapeutics+Enters+Into+Asset+Sale+Agreement+with+Teva+Pharmaceuticals/26992256.html Fri, 28 Aug 2026 06:00:00 -0400 A.04216980 A.06822034 A.07414818 A.27499954 A.37667795 A.50201298 BTAI O.00401804 O.03227691 O.06989819 O.08214736 O.20026344 O.22172153 O.37678149